A Study to Evaluate the Relative Bioavailability of Norethindrone/Ethinyl Estradiol 0.4 mg/0.035 mg Chewable Tablets (Teva Pharmaceuticals, USA) Compared to FEMCON® Fe (Norethindrone/Ethinyl Estradiol) 0.4 mg/0.035 mg Chewable Tablets (Warner Chilcott) in Healthy Female Volunteers Under Non-Fasted Conditions
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Ethinylestradiol/norethisterone (Primary)
- Indications Pregnancy
- Focus Pharmacokinetics
Most Recent Events
- 30 May 2011 Biomarkers information updated
- 02 May 2011 New trial record